MX350661B - Composiciones inmunoterapeuticas de levadura-brachyuri. - Google Patents
Composiciones inmunoterapeuticas de levadura-brachyuri.Info
- Publication number
- MX350661B MX350661B MX2013010475A MX2013010475A MX350661B MX 350661 B MX350661 B MX 350661B MX 2013010475 A MX2013010475 A MX 2013010475A MX 2013010475 A MX2013010475 A MX 2013010475A MX 350661 B MX350661 B MX 350661B
- Authority
- MX
- Mexico
- Prior art keywords
- yeast
- immunotherapeutic compositions
- brachyury immunotherapeutic
- brachyury
- compositions
- Prior art date
Links
- 230000001024 immunotherapeutic effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000014509 gene expression Effects 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6006—Cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
Abstract
La presente invención se refiere a una composición inmunoterapéutica, caracterizada porque comprende: a) un vehículo de levadura; y b) un antígeno de cáncer que comprende por lo menos un antígeno Brachyury, para uso en un método para reducir, suprimir, revertir, retrasar o evitar el progreso metastásico de cáncer en un individuo quien tiene cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161453656P | 2011-03-17 | 2011-03-17 | |
PCT/US2012/029636 WO2012125998A1 (en) | 2011-03-17 | 2012-03-19 | Yeast-brachyury immunotherapeutic compositions |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013010475A MX2013010475A (es) | 2014-05-28 |
MX350661B true MX350661B (es) | 2017-09-13 |
Family
ID=46831122
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013010475A MX350661B (es) | 2011-03-17 | 2012-03-19 | Composiciones inmunoterapeuticas de levadura-brachyuri. |
Country Status (19)
Country | Link |
---|---|
US (5) | US9198941B2 (es) |
EP (2) | EP3238731B1 (es) |
JP (4) | JP6068368B2 (es) |
KR (1) | KR102046449B1 (es) |
CN (1) | CN103648513B (es) |
AU (3) | AU2012228937B2 (es) |
BR (1) | BR112013023456B1 (es) |
CA (1) | CA2835475C (es) |
DK (1) | DK2685995T3 (es) |
ES (1) | ES2627979T3 (es) |
HK (1) | HK1245649A1 (es) |
HU (1) | HUE033491T2 (es) |
IL (1) | IL228421B (es) |
MX (1) | MX350661B (es) |
PL (1) | PL2685995T3 (es) |
PT (1) | PT2685995T (es) |
RU (2) | RU2619850C2 (es) |
SG (2) | SG193396A1 (es) |
WO (1) | WO2012125998A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2170384B1 (en) | 2007-07-02 | 2016-04-13 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
US8877205B2 (en) | 2011-02-12 | 2014-11-04 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis B infection |
AU2012228937B2 (en) | 2011-03-17 | 2016-11-03 | Globeimmune, Inc. | Yeast-Brachyury immunotherapeutic compositions |
ES2671381T3 (es) | 2011-06-14 | 2018-06-06 | Globeimmune, Inc. | Composiciones inmunoterapéuticas para el tratamiento o prevención de infección por virus de hepatitis delta |
RU2642300C2 (ru) | 2011-08-17 | 2018-01-24 | Глоубиммьюн, Инк. | Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения |
CN104685360B (zh) | 2012-06-26 | 2018-02-13 | 比奥德希克斯股份有限公司 | 用于选择和去选择用产生免疫应答的疗法治疗的癌症患者的质谱方法 |
WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
ES2752190T3 (es) | 2012-09-14 | 2020-04-03 | Us Health | Proteína Brachyury, vectores adenovirales que codifican proteína Brachyury y su uso |
MX2015013380A (es) | 2013-03-19 | 2016-01-08 | Globeimmune Inc | Inmunoterapia para cordoma a base de levadura. |
TWI626948B (zh) | 2013-03-26 | 2018-06-21 | 環球免疫公司 | 治療或預防人類免疫缺乏病毒感染之組合物及方法 |
US9725494B2 (en) * | 2013-05-17 | 2017-08-08 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Soluble CD27 (sCD27) and the use thereof |
TWI654200B (zh) | 2013-08-30 | 2019-03-21 | 環球免疫公司 | 治療或預防結核病的組合物及方法 |
WO2015157639A1 (en) | 2014-04-11 | 2015-10-15 | Globeimmune, Inc. | Yeast-based immunotherapy and type i interferon sensitivity |
CA2974237C (en) | 2015-01-09 | 2021-07-20 | Etubics Corporation | Methods and compositions for combination immunotherapy |
EP3286213B1 (en) | 2015-04-20 | 2021-08-04 | Etubics Corporation | Methods and compositions for combination immunotherapy |
CA2994694A1 (en) | 2015-08-03 | 2017-02-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury deletion mutants, non-yeast vectors encoding brachyury deletion mutants, and their use |
TWI748957B (zh) * | 2015-08-03 | 2021-12-11 | 美商環球免疫公司 | 經修飾之酵母-短尾畸型(Brachyury)免疫治療組合物 |
SG11201807770RA (en) | 2016-03-24 | 2018-10-30 | Nantcell Inc | Sequence arrangements and sequences for neoepitope presentation |
US20190125852A1 (en) * | 2016-06-03 | 2019-05-02 | Etubics Corporation | Compositions and methods for tumor vaccination using prostate cancer-associated antigens |
WO2018094190A2 (en) | 2016-11-18 | 2018-05-24 | Sanford Burnham Prebys Medical Discovery Institute | Gut microbiota and treatment of cancer |
AU2018258119B2 (en) | 2017-04-24 | 2021-04-01 | Nantcell, Inc. | Targeted neoepitope vectors and methods therefor |
US11510982B2 (en) * | 2017-08-15 | 2022-11-29 | Nantcell, Inc. | HaNK cetuximab combinations and methods |
EP3793576A4 (en) * | 2018-05-15 | 2022-04-06 | Globeimmune, Inc. | RECOMBINANT YEAST LYSATES FOR INDUCING CELLULAR IMMUNE RESPONSE |
US20210284716A1 (en) | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1036329A (en) | 1908-11-19 | 1912-08-20 | Edison Inc Thomas A | Phonograph-reproducer. |
FR2486400B1 (fr) | 1980-07-09 | 1986-05-30 | Univablot | Medicaments a base de levures ou de leurs extraits insolubles |
NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
US5310654A (en) | 1985-07-31 | 1994-05-10 | The Board Of Trustees Of The Leland Stanford Junior University | Method for determining virulence of Yersinia |
US5234830A (en) | 1988-02-03 | 1993-08-10 | Suntory Limited | DNA encoding a KEX2 endoprotease without a C-terminal hydrophobic region |
IL95019A0 (en) | 1989-08-09 | 1991-06-10 | Mycogen Corp | Process for encapsulation of biologicals |
US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
US5413914A (en) | 1993-07-07 | 1995-05-09 | The Regents Of The University Of Colorado | Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases |
US5858378A (en) | 1996-05-02 | 1999-01-12 | Galagen, Inc. | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen |
US20020044948A1 (en) | 2000-03-15 | 2002-04-18 | Samir Khleif | Methods and compositions for co-stimulation of immunological responses to peptide antigens |
US8153414B2 (en) | 2000-04-06 | 2012-04-10 | Allertein Therapeutics, Llc | Microbial delivery system |
US7083787B2 (en) | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
ES2676503T3 (es) | 2002-12-16 | 2018-07-20 | Globeimmune, Inc. | Vacunas basadas en levadura como inmunoterapia |
US7439042B2 (en) | 2002-12-16 | 2008-10-21 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
US20100034840A1 (en) * | 2005-07-11 | 2010-02-11 | David Apelian | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
US20070172503A1 (en) | 2005-12-13 | 2007-07-26 | Mycologics,Inc. | Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines |
MX2008009929A (es) * | 2006-02-02 | 2008-10-01 | Globeimmune Inc | Vacuna a base de levadura para inducir una respuesta inmune. |
US7745128B2 (en) * | 2006-03-27 | 2010-06-29 | Globeimmune, Inc. | Ras mutation and compositions and methods related thereto |
ES2527756T3 (es) | 2007-02-02 | 2015-01-29 | Globeimmune, Inc. | Procedimientos mejorados de producción de vacunas con base de levadura |
AU2008221383B2 (en) | 2007-02-28 | 2012-09-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Brachyury polypeptides and methods for use |
MX2009010066A (es) | 2007-03-19 | 2009-10-12 | Globeimmune Inc | Composiciones y metodos para la ablacion especifica de la evasion mutacional de terapias especificas para cancer. |
WO2009042642A2 (en) | 2007-09-24 | 2009-04-02 | President And Fellows Of Harvard College | Compositions and methods for the treatment and prevention of ulcerative colitis and colon cancer |
JP2012503011A (ja) | 2008-09-19 | 2012-02-02 | グローブイミューン,インコーポレイテッド | 慢性c型肝炎ウイルス感染の免疫療法 |
WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
US10383924B2 (en) * | 2009-04-17 | 2019-08-20 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
EP2477647B1 (en) | 2009-09-14 | 2016-01-13 | The Regents of the University of Colorado | Modulation of yeast-based immunotherapy products and responses |
WO2011115914A1 (en) | 2010-03-14 | 2011-09-22 | Globeimmune, Inc. | Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy |
WO2012019127A2 (en) * | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
EP2651439B1 (en) | 2010-12-17 | 2018-09-19 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of human adenovirus-36 infection |
US8877205B2 (en) | 2011-02-12 | 2014-11-04 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis B infection |
AU2012228937B2 (en) | 2011-03-17 | 2016-11-03 | Globeimmune, Inc. | Yeast-Brachyury immunotherapeutic compositions |
ES2671381T3 (es) | 2011-06-14 | 2018-06-06 | Globeimmune, Inc. | Composiciones inmunoterapéuticas para el tratamiento o prevención de infección por virus de hepatitis delta |
RU2642300C2 (ru) | 2011-08-17 | 2018-01-24 | Глоубиммьюн, Инк. | Иммунотерапевтические композиции на основе дрожжей-muc1 и способы их применения |
-
2012
- 2012-03-19 AU AU2012228937A patent/AU2012228937B2/en active Active
- 2012-03-19 MX MX2013010475A patent/MX350661B/es active IP Right Grant
- 2012-03-19 ES ES12757534.8T patent/ES2627979T3/es active Active
- 2012-03-19 RU RU2013146324A patent/RU2619850C2/ru active IP Right Revival
- 2012-03-19 SG SG2013068176A patent/SG193396A1/en unknown
- 2012-03-19 CN CN201280023412.6A patent/CN103648513B/zh active Active
- 2012-03-19 RU RU2017116350A patent/RU2690180C2/ru active
- 2012-03-19 KR KR1020137027169A patent/KR102046449B1/ko active IP Right Grant
- 2012-03-19 DK DK12757534.8T patent/DK2685995T3/en active
- 2012-03-19 CA CA2835475A patent/CA2835475C/en active Active
- 2012-03-19 EP EP17154014.9A patent/EP3238731B1/en active Active
- 2012-03-19 EP EP12757534.8A patent/EP2685995B1/en active Active
- 2012-03-19 PL PL12757534T patent/PL2685995T3/pl unknown
- 2012-03-19 WO PCT/US2012/029636 patent/WO2012125998A1/en active Application Filing
- 2012-03-19 BR BR112013023456-3A patent/BR112013023456B1/pt active IP Right Grant
- 2012-03-19 SG SG10201601913RA patent/SG10201601913RA/en unknown
- 2012-03-19 JP JP2013558234A patent/JP6068368B2/ja active Active
- 2012-03-19 PT PT127575348T patent/PT2685995T/pt unknown
- 2012-03-19 HU HUE12757534A patent/HUE033491T2/en unknown
-
2013
- 2013-03-14 US US13/803,719 patent/US9198941B2/en active Active
- 2013-09-12 IL IL228421A patent/IL228421B/en active IP Right Grant
-
2015
- 2015-10-29 US US14/926,372 patent/US9623097B2/en active Active
-
2016
- 2016-12-22 JP JP2016249307A patent/JP6309607B2/ja active Active
-
2017
- 2017-02-02 AU AU2017200715A patent/AU2017200715B2/en active Active
- 2017-03-09 US US15/454,176 patent/US10363294B2/en active Active
-
2018
- 2018-03-14 JP JP2018046148A patent/JP6580733B2/ja active Active
- 2018-04-19 HK HK18105126.6A patent/HK1245649A1/zh unknown
- 2018-04-30 AU AU2018202972A patent/AU2018202972B2/en active Active
-
2019
- 2019-04-19 US US16/389,235 patent/US11944673B2/en active Active
- 2019-08-28 JP JP2019155138A patent/JP2019199484A/ja active Pending
-
2020
- 2020-12-21 US US17/129,633 patent/US11938175B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX350661B (es) | Composiciones inmunoterapeuticas de levadura-brachyuri. | |
MX2014001717A (es) | Composiciones inmunoterapeuticas de levadura-mucina 1 (muc1) y usos de las mismas. | |
MY184101A (en) | Indoles | |
MX2014009289A (es) | Anticuerpos c1orf32 y usos de los mismos para el tratamiento del cancer. | |
PH12014502601A1 (en) | ANTI-Ly6E ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | |
PH12014502132A1 (en) | Anti-lgr5 antibodies and immunoconjugates | |
PH12017500864A1 (en) | Anti-notch1 antibodies | |
EP2714081A4 (en) | METHODS, COMPOSITIONS AND KIT FOR CREAM TREATMENT | |
MX2013011479A (es) | Anticuerpos anti-fgfr4 y metodos de uso. | |
PH12015501059A1 (en) | Anti-hemagglutinin antibodies and methods of use | |
MX2014002053A (es) | Anticuerpos anti -mcsp y metodos de uso. | |
MX2014004022A (es) | Anticuerpos anti-htra1 y metodos de uso. | |
EA201201000A1 (ru) | Способы лечения колоректального рака | |
MX354988B (es) | Formulaciones de anticuerpo y metodos. | |
TN2013000378A1 (en) | Anti - sclerostin antibody crystals and formulations thereof | |
MX2013001473A (es) | Anticuerpos contra il-18r1 y usos de los mismos. | |
MY157341A (en) | Methods and compositions for treating lung cancer | |
JO3755B1 (ar) | تركيبات تستوستيرون | |
MX2013013706A (es) | Peptidoglicanos sinteticos de union a acido hialuronico, su preparacion y metodos de uso. | |
IN2014DN05885A (es) | ||
IN2014DN09450A (es) | ||
EP4023243A3 (en) | Compositions and methods for treating celiac sprue disease | |
WO2012149334A3 (en) | Methods and compositions for the generation and use of conformation-specific antibodies | |
IN2014DN00254A (es) | ||
WO2013052108A3 (en) | Methods and compositions for the treatment and diagnosis of ovarian cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |